← Leaderboards
Jacek Pinski
University Of Southern California
$3,050,227
Attributed
$5,282,342
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $676.6K · FY2007–18$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$5,282,342 · 6
By mechanism
R01$4,889,952 · 2
M01$230,120 · 3
R21$162,270 · 1
Top collaborators
- Amir Goldkorn5 shared
- Sue Ann Ingles5 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Fred R Sattler$24,195,984
- Sue Ann Ingles$3,809,981
- Amir Goldkorn$4,457,420
- Bodour Salhia$4,072,298
- Craig A Knoblock$1,480,030
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseTumorBlood SpecimenSpecimenMalignant Neoplasm Of ProstateBasePrimary NeoplasmLuteinizing Hormone-Releasing Hormone AgonistCellsTechnologyResearch PersonnelDrug KineticsNeoplastic CellCancer CellAndrogen ReceptorSafetyPublic Health RelevanceHormone TherapyAndrogensNeoplasm Circulating CellsClinical ResearchBiologyBiological MarkersBiological
Grant awards (14)
Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial$662,099
R01 · FY2018 · CA
Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial$665,642
R01 · FY2017 · CA
Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial$669,388
R01 · FY2016 · CA
Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial$676,561
R01 · FY2015 · CA
Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial$674,482
R01 · FY2014 · CA
Targeted Therapy to Receptors for LH-RH in Prostate Cancer$303,475
R01 · FY2013 · CA · contact PI
Targeted Therapy to Receptors for LH-RH in Prostate Cancer$179,414
R01 · FY2012 · CA · contact PI
Targeted Therapy to Receptors for LH-RH in Prostate Cancer$510,432
R01 · FY2011 · CA · contact PI
Targeted Therapy to Receptors for LH-RH in Prostate Cancer$548,459
R01 · FY2010 · CA · contact PI
PHI-54 A PHASE I STUDY OF IV FENRETINIDE IN PATIENTS WITH MALIGNANT SOLID TU$204,070
M01 · FY2009 · RR · contact PI
PHI-54 A PHASE I STUDY OF IV FENRETINIDE IN PATIENTS WITH MALIGNANT SOLID TU$14,421
M01 · FY2008 · RR · contact PI
PHI-54 A PHASE I STUDY OF IV FENRETINIDE IN PATIENTS WITH MALIGNANT SOLID TU$11,629
M01 · FY2007 · RR · contact PI
AR signaling in Hormone Refractory Prostate Cancer$81,250
R21 · FY2004 · DK
AR signaling in Hormone Refractory Prostate Cancer$81,020
R21 · FY2003 · DK